MD · MBA
Physician specializing in genetic analysis and personalized preventive medicine, and author of Outsmart Your Genes.
Brandon Colby is a physician-expert in the fields of genetic analysis and Personalized Preventive Medicine. He holds an MD from the Mount Sinai School of Medicine, an MBA from Stanford University's Graduate School of Business, and a degree in Genetics from the University of Michigan.
Dr. Colby is the author of the book Outsmart Your Genes and has developed numerous technologies that improve the analysis, interpretation, and actionability of genome sequencing data. He is an Affiliate Specialist of the American College of Medical Genetics and Genomics (ACMG), an Associate of the American College of Preventive Medicine (ACPM), and a member of the National Society of Genetic Counselors (NSGC).
Articles by Brandon Colby, MD are reviewed for accuracy by Sequencing's medical and scientific team. This page is for informational purposes and does not constitute medical advice.
Language delays, ADHD, cognitive impairment and sometimes cardiac arrhythmia trace back to GNB5 variants, which testing can identify for families.
Reduced fetal movement and joint contractures may appear on prenatal ultrasound, and GLDN variants confirm LCCS11 for genetic counseling.
Developmental delay, hypotonia, seizures, cataracts and cardiomyopathy with left ventricular non-compaction define this neurometabolic disease, confirmed by DNA analysis.
A variant in BAIAP2 disturbs the cytoskeleton and cell movement, leaving the cortex smooth. Genetic testing supports early diagnosis and treatment choices.
Chronic lung disease, weakened immune defense and chromosome breakage form the LICS triad, rooted in DNA repair mutations; genetic testing supports early diagnosis.
Cystic, lymph-filled structures form when lymphatic vessel genes are altered. LM7 diagnosis, targeted therapy prospects and genetic counseling are discussed.
Inheriting two altered copies, one from each parent, is what produces Microcephaly 17; testing shows which mutation is involved and supports early therapy.
A small jaw, repeated infections, behavioral changes and mild intellectual disability make up MRIBAMID, where testing may flag MN1 or variants of uncertain significance.